In vivo differentiation of blast-phase chronic granulocytic leukemia. Expression of c-myc and c-abl protooncogenes.

C A Koller; V W Campbell; D A Polansky; A Mulhern; D M Miller

doi:10.1172/JCI111970

Find articles by Koller, C. in: PubMed | Google Scholar

Find articles by Campbell, V. in: PubMed | Google Scholar

Find articles by Polansky, D. in: PubMed | Google Scholar

Find articles by Mulhern, A. in: PubMed | Google Scholar

Find articles by Miller, D. in: PubMed | Google Scholar

Published in Volume 76, Issue 1 on July 1, 1985
J Clin Invest. 1985;76(1):365–369. https://doi.org/10.1172/JCI111970.
© 1985 The American Society for Clinical Investigation

Published July 1, 1985 - Version history

A patient with chronic granulocytic leukemia in acute blastic transformation was treated with mithramycin, an RNA synthesis inhibitor, after in vitro exposure of her leukemic cells to mithramycin showed differentiation to normal appearing granulocytes. Mithramycin therapy in vivo resulted in a prompt and dramatic hematologic response. Before therapy, the patient's leukemic cells had high levels of transcription of the cellular myc and abl protooncogenes. After initiation of therapy, protooncogene mRNA decreased rapidly. These observations indicate that mithramycin can induce differentiation both in vitro and in vivo and suggest that such changes may be associated with altered oncogene expression.

Images.

Click on an image below to see the page. View PDF of the complete article